A possible role for sarcosine in the management of schizophrenia. (December 2019)

• Record Type: Journal Article
• Authors: Curtis, David
• Is Part Of: British journal of psychiatry. Volume 215:Number 6(2019)
• Page Start: 697
• Page End: 698
• Publication Date: 2019-12
• Subjects: Sarcosine, -- schizophrenia, -- glutamate, -- glycine, -- pharmacology; Psychiatry -- Periodicals; Psychology, Pathological -- Periodicals; 616.89005
• DOI: 10.1192/bjp.2019.194
• Languages: English
• ISSNs: 0007-1250

Abstract

Summary: Sarcosine, which is freely sold as a dietary supplement, has pharmacological activity to boost functioning of the glutamatergic N -methyl-d -aspartate receptor (NMDAR) and hence it is a biologically rational treatment for schizophrenia. The small number of studies carried out to date provide some evidence for its efficacy and psychiatrists could consider suggesting its use to their patients.